CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer
This higher dose is specifically designed for severe injuries, major surgical recovery, or chronic conditions that require intensive healing support beyond what standard dosing can provide
However, this combination has not been formally studied
This is a preview of subscription content, access via your institution Access options Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription $32.99 / 30 days cancel any time Subscribe to this journal Receive 12 print issues and online access $189.00 per year only $15.75 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF
In studies with mouse models of NAFLD and acute kidney injury (AKI), treatment with ACMSD inhibitors increased the transcription of mitochondrial and -oxidation genes, as well as restoring NAD + levels in the kidney and liver 235